Company news
Johnson & Johnson news
Latest news releases, newest first. Pick a year for every news release, call and deck from that year.
Johnson & Johnson data in psoriatic arthritis (PsA) shows TREMFYA (guselkumab) is the only advanced therapy to demonstrate MRI-confirmed improvements in spinal pain and stiffness
November 20, 2026
Late-breaking Johnson & Johnson data in psoriatic arthritis (PsA) shows TREMFYA® (guselkumab) is the only advanced therapy to demonstrate MRI-confirmed improvements in spinal pain and stiffness
November 20, 2026
Johnson & Johnson Announces First Commercial Installation of the OTTAVA™ Robotic Surgical System at Memorial Hermann Health System
November 19, 2026
Johnson & Johnson Announces First Commercial Installation of the OTTAVATM Robotic Surgical System at Memorial Hermann Health System
November 19, 2026
Johnson & Johnson Seeks U.S. FDA Approval for CAPLYTA in Bipolar Mania, Marking Fifth Potential Indication
November 19, 2026
Johnson & Johnson to Present 13 Abstracts Advancing Neurovascular Science at SVIN 2026
November 17, 2026
Johnson & Johnson Receives FDA Clearance for Expanded U.S. Ear, Nose and Throat (ENT) Indication for HARMONICTM 1100 Shears
November 16, 2026
Johnson & Johnson to acquire Ollin Biosciences and late-stage bispecific antibody with best-in-class potential in ophthalmology
November 16, 2026
California Jury Awards $34.21 Million in Johnson & Johnson Talc-Asbestos Mesothelioma Case
November 10, 2026
Johnson & Johnson Announces CAPLYTA (lumateperone) Shows Significant and Rapid Improvement in Bipolar Mania in Second Pivotal Phase 3 Study
November 10, 2026
Johnson & Johnson reports 73% PSA response rate with investigational pasritamig-based immunotherapy combination in advanced prostate cancer
November 8, 2026
Johnson & Johnson announces new Phase 2 nipocalimab study data in Sjögren's disease that reveal insights on importance of symptom improvements most valued by patients
November 7, 2026
Johnson & Johnson announces ICOTYDE® (icotrokinra) delivers significant improvement in psoriatic arthritis disease activity among biologic-naive patients with once-daily targeted oral peptide
November 7, 2026
Johnson & Johnson announces U.S. FDA Approval of RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) as First and Only Dual-Targeted Therapy for Advanced Head and Neck Cancer
November 5, 2026
Data Show Positive Survival and Patient Outcomes with Best-Practice Impella Support in HRPCI, in Contrast to CHIP-BCIS3 Study Results
November 1, 2026
Johnson & Johnson: Record 26 Abstracts at TCT 2026 Adds to More than 20 Years of Data Demonstrating the Safety, Efficacy and Cost Effectiveness of Impella Heart Pumps
October 29, 2026
Johnson & Johnson to Host Enterprise Business Review
October 27, 2026
Subcutaneous RYBREVANT®▼ (amivantamab) demonstrates 77% overall response rate in first-line treatment of patients with certain types of advanced head and neck cancer
October 25, 2026
RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) combination demonstrates 77% overall response rate in first-line treatment of patients with advanced head and neck cancer
October 25, 2026
Johnson & Johnson reports 75% tumor response rate in advanced prostate cancer with JNJ-6143, a first-in-class RIPTAC™ molecule
October 25, 2026
Johnson & Johnson announces ERLEADA® (apalutamide) treatment before and after surgery reduces risk of recurrence or death by 62% versus surgery alone in high-risk localised or locally advanced prostate cancer
October 24, 2026
Johnson & Johnson announces ERLEADA® (apalutamide) treatment before and after surgery reduces risk of recurrence or death by 62% versus surgery alone in high-risk prostate cancer
October 24, 2026
Johnson & Johnson advances the next generation of solid tumor therapies with new data at ESMO 2026
October 23, 2026
European Commission approves Johnson & Johnson’s TECVAYLI®▼ (teclistamab) monotherapy for relapsed/refractory multiple myeloma, expanding treatment options from first relapse
October 23, 2026
Quarterly Report for Quarter Ending September 27, 2026 (Form 10-Q)
October 21, 2026
Johnson & Johnson Launches Next-Generation Shockwave™ C2 Aero Fly Coronary IVL Catheter, Cutting IVL Treatment Time in Half
October 20, 2026
Johnson & Johnson to Showcase the Future of Surgical Intelligence at Abu Dhabi Future Health Summit 2026
October 20, 2026
Johnson & Johnson announces new data showing TREMFYA (guselkumab) is the only IL-23 to deliver durable fistula remission through 48 weeks in Crohn’s disease with perianal fistula
October 19, 2026
Johnson & Johnson announces new TREMFYA® (guselkumab) data showing durable 3-year outcomes in moderate to severe Crohn’s disease and expanding evidence in perianal fistula
October 19, 2026
Johnson & Johnson announces new data showing TREMFYA® (guselkumab) is the only IL-23 to deliver durable fistula remission through 48 weeks in Crohn's disease with perianal fistula
October 19, 2026
CHMP recommends approval of Johnson & Johnson’s TALVEY®▼ (talquetamab) plus daratumumab in earlier line treatment of relapsed/refractory multiple myeloma
October 16, 2026
Johnson & Johnson Q3 2026 earnings: CEO and CFO prepared remarks
October 13, 2026
Johnson & Johnson Announces Quarterly Dividend for Fourth Quarter 2026
October 13, 2026
Johnson & Johnson reports Q3 2026 results, raises 2026 guidance
October 13, 2026
TREMFYA® (guselkumab) demonstrated sustained clinical and endoscopic remission through 3 years in moderately to severely active Crohn's disease
October 12, 2026
New TREMFYA® (guselkumab) study shows consistent perianal fistula remission across key Crohn's disease patient subgroups
October 12, 2026
New Johnson & Johnson ICOTYDE® (icotrokinra) long-term data demonstrate robust 2-year results in the treatment of adults and adolescents with plaque psoriasis
October 9, 2026
Johnson & Johnson announces new ICOTYDE® (icotrokinra) data in difficult-to-treat plaque psoriasis with proven durability through 2-years, affirming its use as a powerful first line systemic therapy
October 2, 2026
LISTERINE® Launches Oral Care Counts This World Smile Day as Oral Disease Cases Rise to 3.73 Billion
October 1, 2026
Neutrogena®, Aveeno®, and Regaine® Present New Scientific Evidence Demonstrating How Science-Backed Ingredients Support Healthy Skin and Hair
September 30, 2026
Johnson & Johnson presents new data reinforcing sustained disease control and improved daily function achieved with IMAAVY® (nipocalimab-aahu) in generalized myasthenia gravis (gMG)
September 29, 2026
Johnson & Johnson announces TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to show significant improvement in spinal pain and stiffness in landmark axial psoriatic arthritis (PsA) study
September 25, 2026
Single infusion of CARVYKTI®▼ (ciltacabtagene autoleucel) delivered five-year treatment-free remissions in 50% of patients in early line relapsed/refractory multiple myeloma
September 25, 2026
Single infusion of CARVYKTI® (ciltacabtagene autoleucel) delivered five-year treatment-free remissions in 50% of patients in early line relapsed/refractory multiple myeloma
September 25, 2026
New model-based analysis further supports the potential of TECVAYLI®▼ (teclistamab) plus daratumumab to redefine long-term survival expectations in early line relapsed/refractory multiple myeloma
September 23, 2026
New model-based analysis further supports the potential of TECVAYLI® (teclistamab-cqyv) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) to redefine long-term survival expectations in early line relapsed/refractory multiple myeloma
September 23, 2026
European Commission approval of ICOTYDE™▼(icotrokinra) ushers in new era for first-line systemic treatment of plaque psoriasis with a targeted oral peptide
September 21, 2026
CAPLYTA® (lumateperone) shows significant and rapid improvement in bipolar mania in pivotal Phase 3 study
September 21, 2026
CHMP recommends approval of Johnson & Johnson’s TECVAYLI®▼ (teclistamab) in relapsed/refractory multiple myeloma after at least one prior therapy
September 18, 2026
RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) plus LAZCLUZE® (lazertinib) with prophylactic strategies shows low rates of treatment-related events at WCLC 2026
September 13, 2026
Calls
The 5 newest of 31 calls. Every call is listed under its year.
- Johnson & Johnson (NYSE:JNJ) Q3 2026 Earnings Call
Oct 13, 2026
Transcript - Johnson & Johnson (NYSE:JNJ) Q2 2026 Earnings Call
Jul 15, 2026
Transcript - Johnson & Johnson (NYSE:JNJ) Q1 2026 Earnings Call
Apr 14, 2026
Transcript - Johnson & Johnson (NYSE:JNJ) Q4 2025 Earnings Call
Jan 21, 2026
Transcript - Johnson & Johnson (NYSE:JNJ) Q3 2025 Earnings Call
Oct 14, 2025
Transcript
Decks
The 5 newest of 69 decks. Every deck is listed under its year.
- Q3 2026 Earnings Presentation
Earnings · 27 slides · Oct 13, 2026
- Q2 2026 Earnings Presentation
Earnings · 24 slides · Jul 15, 2026
- Q1 2026 Earnings Presentation
Earnings · 28 slides · Apr 14, 2026
- Q4 2025 Earnings Presentation
Earnings · 33 slides · Jan 21, 2026
- Q3 2025 Earnings Presentation
Earnings · 26 slides · Oct 14, 2025